We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GV:NASDAQVisionary Holdings Inc. Analysis

Data as of 2026-04-07 - not real-time

$0.34

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Visionary Holdings (GV) is trading at $0.34, well below its 20‑day SMA of 0.37 and far under the 50‑day SMA of 0.79, indicating a short‑term bearish bias. The 30‑day volatility of 288% and a max drawdown of -92.9% underscore extreme price swings, while a beta of 0.56 suggests modest correlation to the broader market. Technical momentum is mixed: RSI sits at 40 (near‑neutral) and the MACD line sits above its signal, generating a bullish histogram signal, yet the overall trend remains bearish with price trapped between a support of 0.181 and resistance near 0.715. Fundamentals are weak – operating margin is deeply negative (-194%), debt‑to‑equity exceeds 900, and the company reports no earnings or cash flow positivity. The balance sheet is strained, with cash of only $0.33 M against debt of $48.6 M, and the price‑to‑book ratio of 0.38 reflects a market discount to net assets.
Recent news highlights a strategic pivot: GV announced a 2026‑2027 outlook targeting $30 million annual sales from its RAMU anti‑aging line and confirmed regained compliance with Nasdaq filing rules, removing an immediate regulatory threat. If the anti‑aging products achieve even a fraction of the forecast, revenue could improve, but the company must first reverse cash burn and resolve its capital structure before the upside can be realized.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below short‑term moving averages
  • Extreme short‑term volatility
  • Negative earnings and cash flow

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Nasdaq compliance restored
  • Potential revenue from anti‑aging product line
  • Continued cash‑burn and high leverage

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Low price‑to‑book valuation
  • Strategic expansion into health and AI education
  • Long‑run upside if $30 M sales target is met

Key Metrics & Analysis

Financial Health

Revenue Growth-61.70%
ROE-137.27%
ROA-2.86%
Debt/Equity934.98
P/B Ratio0.4
Op. Cash Flow$-2968384
Free Cash Flow$-520235

Technical Analysis

TrendBearish
RSI40.3
Support$0.18
Resistance$0.71
MA 20$0.37
MA 50$0.79
MA 200$1.39
MACDBullish
VolumeIncreasing
Fear & Greed Index77.75

Valuation

GradeUndervalued
TypeBlend

Risk Assessment

Beta0.56
Volatility288.91%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.